TITLE

Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud

AUTHOR(S)
Lemieux, Bernard; Bouafia, Fadhela; Thieblemont, Catherine; Hequet, Olivier; Arnaud, Philippe; Tartas, Sophie; Traulle, Catherine; Salles, Gilles; Coiffier, Bertrand
PUB. DATE
November 2004
SOURCE
Hematology Journal;2004, Vol. 5 Issue 6, p467
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The purpose of this study was to evaluate retrospectively the effect of a second treatment with rituximab for patients who progressed after a response to a first treatment. We analysed the charts of 41 patients treated at CHU Lyon-Sud between 1997 and May 2003. Patients were treated with rituximab alone or with a combination of rituximab and chemotherapy. The overall response rate (complete and partial response) was 73%for the second treatment. The median time to progression was longer but not significant for the second treatment in comparison with the first one (15.2 versus 11.3 months, P=0.09). The second treatment was well tolerated. Thus, a second treatment with rituximab should be considered, alone or in combination with chemotherapy, for patients who progress after a first response to rituximab.The Hematology Journal (2004) 5, 467-471. doi:10.1038/sj.thj.6200559
ACCESSION #
15229754

 

Related Articles

  • A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma. Arcaini, L; Orlandi, E; Alessandrino, Ep; Iacona, I; Brusamolino, E; Bonfichi, M; Bernasconi, P; Calatroni, S; Tenore, A; Montanari, F; Troletti, D; Pascutto, C; Regazzi, M; Lazzarino, M // Bone Marrow Transplantation;Jul2004, Vol. 34 Issue 2, p175 

    Summary:We studied a model of in vivo purging with Rituximab and high-dose (HD) cytarabine in 14 patients with relapsed/refractory follicular lymphoma and two with refractory mantle cell lymphoma enrolled in a program of HD chemotherapy and autotransplant. After two courses of debulking...

  • Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. Borgerding, Andrea; Hasenkamp, Justin; Glaß, Bertram; Wulf, Gerald; Trümper, Lorenz // Annals of Hematology;Mar2010, Vol. 89 Issue 3, p283 

    Neither effective salvage regimens nor the outcome and response to retherapy with rituximab containing chemotherapy have been defined for rituximab pre-treated patients with relapsing aggressive lymphoma. We report here a single-centre retrospective outcome analysis of second-line...

  • Rituximab therapy in malignant lymphoma. Coiffier, B. // Oncogene;5/28/2007, Vol. 26 Issue 25, p3603 

    Rituximab is the first monoclonal antibody to have been registered for the treatment of B-cell lymphomas. Randomized studies haves demonstrated its activity in follicular lymphoma (FL), mantle cell lymphoma and diffuse large B-cell lymphoma (DLBCL) in untreated or relapsing patients....

  • Immunothérapie des lymphomes. Reyes, F. // Oncologie;mai2006, Vol. 8 Issue 4, p331 

    Rituximab is the first monoclonal antibody to have been registered for the treatment of aggressive and indolent, untreated or relapsed B-cell lymphomas. The combination of rituximab with chemotherapy, such as R-CHOP, has the highest efficacy ever described with any chemotherapy regimen....

  • Spotlight on Rituximab in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia1. Cvetković, Risto S.; Perry, Caroline M. // BioDrugs;2006, Vol. 20 Issue 4, p253 

    Rituximab (MabThera, Rituxan) is an anti-CD20 monoclonal antibody that induces lysis and apoptosis of normal and malignant human B cells, and sensitizes malignant B cells to the cytotoxic effect of chemotherapy. In phase III trials in patients with indolent or aggressive B-cell non-Hodgkin...

  • Acute painful lumbosacral paresthesia after intrathecal rituximab. Bromberg, J.; Doorduijn, J.; Baars, J.; Imhoff, G.; Enting, R.; Bent, M. // Journal of Neurology;Mar2012, Vol. 259 Issue 3, p559 

    The article presents a study that determines the effectiveness of rituximab in patient with recurrent aggressive B-cell lymphoma with central nervous system (CNS) localization. It outlines the method of the study in which patients were treated with rituximab without preservatives. It outlines...

  • Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Kanungo, Anuradha; Medeiros, L. Jeffrey; Abruzzo, Lynne V.; Pei Lin // Modern Pathology;Jan2006, Vol. 19 Issue 1, p25 

    We identified 14 B-cell neoplasms with concurrent t(14;18) and chromosome 8q24 or c-MYC translocations shown by conventional cytogenetics or fluorescence in situ hybridization analysis. All cases assessed by conventional cytogenetics had a complex karyotype. There were 10 men and four women,...

  • An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. Shams'ili, Setareh; De Beukelaar, Janet; Gratama, Jan; Hooijkaas, Herbert; Van Den Bent, Martin; Van't Veer, Mars; Sillevis Smitt, Peter // Journal of Neurology;Jan2006, Vol. 253 Issue 1, p16 

    Anti-CD20 monoclonal antibody (rituximab) is effectively used in the treatment of B-cell lymphomas. Recent reports in the literature suggest that antibody associated autoimmune disorders may respond to rituximab. We therefore treated nine patients with anti-Hu or anti-Yo associated...

  • Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14+R) in high-risk diffuse large cell lymphoma. Agustin Avilés; María Nambo; Natividad Neri; Sergio Cleto; Claudia Castañeda; Judith Huerta-Guzmàn; Edgar Murillo; Margarita Contreras; Alejandra Talavera; Martha González // Medical Oncology;Jan2007, Vol. 24 Issue 1, p85 

    Abstract  To assess efficacy and toxicity of rituximab and dose chemotherapy in high-risk diffuse large cell lymphoma, we conducted a controlled clinical trial to assess efficacy and toxicity of a dose-dense regimen CEOP-14 (cyclophosphamide, epirubicin, vincristine, and prednisone every...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics